Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Trial Profile

A Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BT-11 (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Landos Biopharma
  • Most Recent Events

    • 15 May 2019 Landos will present results at the 2019 Digestive Disease Week (DDW), as reported in a media release.
    • 15 May 2019 According to a Landos Biopharma media release, The publication was authored by company researchers , the Icahn School of Medicine at Mount Sinai and Royal Adelaide Hospital
    • 15 May 2019 According to a Landos Biopharma media release, full results published in Inflammatory Bowel Diseases Journal of the CrohnsColitisFn.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top